Skip to content

Do Iron Supplements Impact the Gut Microbiome of Women of Reproductive Age?

Do Iron Supplements Impact the Gut Microbiome of Women of Reproductive Age?

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05033483
Enrollment
82
Registered
2021-09-02
Start date
2021-08-31
Completion date
2022-01-01
Last updated
2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anemia, Iron-deficiency, Microbial Colonization

Keywords

iron supplements, microbiome, women

Brief summary

In this randomised controlled trial the investigators will determine whether taking iron supplements compared to placebo for 21 days alters the bacteria (microbiome) in the large intestine of non-pregnant female participants.

Detailed description

BACKGROUND: Many women take iron-containing supplements during pregnancy. Indeed, the World Health Organization recommends that all pregnant women in low-income countries take an iron supplement containing 60 mg/day of elemental iron to reduce iron deficiency and iron-deficiency anaemia. However, oral iron has poor bioavailability, less than 10% absorbed with the remainder passing into the large intestine unbound, potentially providing a competitive advantage to iron-dependent opportunistic pathogens in the large intestine. In a large randomized control trial in children, iron supplementation was shown to promote the growth of pathogenic species (E. coli, S. aureus, and L. monocytogenes) and inhibited the growth of commensal species (Lactobacillus and Bifidobacterium). These pathogens are associated with enteric infections, while the commensals act on the host's immune system to prevent colonization and invasion by pathogens. It is NOT known if iron supplementation during pregnancy impacts the maternal and infant microbiome and, by extension, how this affects the neonatal risk of infection and immune dysregulation. Vertical transmission of the maternal microbiome to the newborn is a major determinant of infant health. If maternal iron supplementation affects the infant's health, strategies would be required to mitigate this risk. The investigators require preliminary data to show how oral iron supplementation alters the intestinal microbiome in women. The Investigators will recruit non-pregnant female participants as there is no risk of vertical transmission to an infant in non-pregnant women. The investigators will conduct the study in Australia because there is not a natural abundance of pathogens that could potentially cause harm to the women. Nevertheless, the investigators would expect a shift in the microbiome from non-iron to iron, requiring bacterial species to return to baseline after women stop taking the iron. HYPOTHESIS: Daily iron supplementation versus placebo for 21 days will alter the stool microbiome composition compared to placebo in non-pregnant female participants of reproductive age. METHODS: 80 female participants (18-45 y) will be randomized to receive capsules containing iron (65.7 mg of elemental iron as ferrous fumarate) or placebo to take daily for 21 days. Stool samples will be collected at baseline, 21 days, and 42 days (washout).

Interventions

DIETARY_SUPPLEMENTFerrous Fumarate

Gelatin capsule containing 200 mg ferrous fumarate and microcrystalline cellulose

DIETARY_SUPPLEMENTPlacebo

Gelatin capsule containing microcrystalline cellulose

Sponsors

Flinders University
CollaboratorOTHER
South Australian Health and Medical Research Institute
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Masking description

Supplements were packaged by LifeCare Compounding Pharmacy and labelled by staff not involved in the trial, with 2 colours per treatment group. The randomisation schedule was prepared by an independent statistician. The schedule allocates women to one of the four colours in the ratio 1:1:1:1 using randomly permuted blocks.

Intervention model description

A randomized, controlled, researcher and participant blinded trial with two parallel groups

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

* Able to give informed consent

Exclusion criteria

* Pregnant or breastfeeding. * Planning on becoming pregnant * Diagnosed with iron deficiency and/or anaemia in the previous three months * Taken antibiotics in the past three months * Taken iron containing supplements in the past three months

Design outcomes

Primary

MeasureTime frameDescription
Weighted UniFrac dissimilarity score21 daysMeasure of microbiota beta-diversity

Secondary

MeasureTime frameDescription
Bray-Curtis dissimilarity score21 daysMeasure of microbiota beta-diversity
Shannon Wiener Diversity21 daysMicrobiota alpha-diversity score with adjustment for baseline levels
Faith's phylogenetic diversity21 daysMicrobiota alpha-diversity score with adjustment for baseline levels
Taxonomic richness21 daysMicrobiota alpha-diversity score with adjustment for baseline levels
Relative abundance of core bacterial taxa21 daysRelative abundance of taxa present in \>40% of baseline samples, with adjustment for baseline levels

Other

MeasureTime frameDescription
Weighted UniFrac dissimilarity score42 days (washout)Measure of microbiota beta-diversity
Shannon-Wiener diversity42 days (washout)Microbiota alpha-diversity score with adjustment for baseline levels
Bray-Curtis dissimilarity score42 days (washout)Measure of microbiota beta-diversity
Faith's phylogenetic diversity42 days (washout)Microbiota alpha-diversity score with adjustment for baseline levels
Taxonomic richness42 days (washout)Microbiota alpha-diversity score with adjustment for baseline levels
Relative abundance of core bacterial taxa42 days (washout)Relative abundance of taxa present in \>40% of baseline samples, with adjustment for baseline levels

Countries

Australia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 8, 2026